ATE437951T1 - Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 - Google Patents

Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2

Info

Publication number
ATE437951T1
ATE437951T1 AT98922096T AT98922096T ATE437951T1 AT E437951 T1 ATE437951 T1 AT E437951T1 AT 98922096 T AT98922096 T AT 98922096T AT 98922096 T AT98922096 T AT 98922096T AT E437951 T1 ATE437951 T1 AT E437951T1
Authority
AT
Austria
Prior art keywords
hepatitis
polypeptide
shortened
intracellular production
truncated
Prior art date
Application number
AT98922096T
Other languages
English (en)
Inventor
Michael Hougton
Qui-Lim Choo
Sergio Abrignani
David Chien
Mark Selby
Edward Glazer
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE437951T1 publication Critical patent/ATE437951T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/923—Cell culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98922096T 1997-05-06 1998-05-06 Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 ATE437951T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4567597P 1997-05-06 1997-05-06
PCT/US1998/009097 WO1998050556A2 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides

Publications (1)

Publication Number Publication Date
ATE437951T1 true ATE437951T1 (de) 2009-08-15

Family

ID=21939272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98922096T ATE437951T1 (de) 1997-05-06 1998-05-06 Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2

Country Status (9)

Country Link
US (2) US6521423B1 (de)
EP (1) EP0980434B1 (de)
JP (3) JP4458556B2 (de)
AT (1) ATE437951T1 (de)
AU (1) AU7471698A (de)
CA (1) CA2288374A1 (de)
DE (1) DE69841015D1 (de)
ES (1) ES2328536T3 (de)
WO (1) WO1998050556A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066033A1 (en) * 1998-06-18 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtha Nd Human Services Surface targeted expression of a modified hepatitis c virus envelope protein
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
ES2411096T3 (es) 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
US7329408B2 (en) 1999-12-01 2008-02-12 Novartis Vaccines And Diagnostics, Inc. Eliciting HCV-specific antibodies
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1624785B1 (de) * 2003-01-17 2013-07-17 Aethlon Medical, Inc. Verfahren zur entfernung von viren aus dem blut durch lektin-affinitäts-hämodialyse
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1574517A1 (de) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
EP1602664A1 (de) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 beinhaltend spezifische Disulfidbrücken
KR100894150B1 (ko) * 2004-06-25 2009-04-22 가부시끼가이샤 센단세메이가가꾸겐큐죠 신규한 배열을 가진 ｈｃｖ ｒｎａ
KR20070068460A (ko) * 2004-10-18 2007-06-29 글로브이뮨 만성 ｃ형 간염에 대한 효모계 치료
EP1948802A4 (de) * 2005-10-13 2009-01-14 Virexx Medical Corp Chimäres antigen mit hepatitis-c-virus-polypeptid und fc-fragment zum hervorrufen einer immunantwort
AU2008335457B2 (en) 2007-12-07 2015-04-16 Glaxosmithkline Biologicals S.A. Compositions for inducing immune responses
EP2331125A4 (de) 2008-09-19 2013-03-27 Globeimmune Inc Immuntherapie zur für chronische hepatitis-c-virus-infektionen
CN112999344A (zh) 2013-05-15 2021-06-22 阿尔伯达大学董事会 E1e2 hcv疫苗及使用方法
CA2986342C (en) 2015-07-07 2024-04-02 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
CN117229414A (zh) 2015-10-08 2023-12-15 艾伯塔大学理事会 丙型肝炎病毒e1/e2异二聚体及其生产方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
HUT54896A (en) 1989-03-17 1991-04-29 Chiron Corp Process for producing aquous diagnosticum and vaccine of nanbv
WO1990014436A1 (en) 1989-05-18 1990-11-29 Chiron Corporation Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
DE69131882T3 (de) 1990-11-08 2007-05-24 Novartis Vaccines and Diagnostics, Inc., Emeryville Asiloglycoproteine des hepatitis c-virus
AU3241095A (en) 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
ES2244965T3 (es) * 1994-07-29 2005-12-16 Chiron Corporation Complejos e1/e2 secretados de virus de la hepatitis c obtenidos de polipeptidos e1 y e2 truncados en c-terminal.
EP1845108A3 (de) 1994-07-29 2007-10-24 Innogenetics N.V. Monoklonale Antikörper gegen gereinigte Hüllproteine des Hepatitis-C-Virus für diagnostische und therapeutische Zwecke

Also Published As

Publication number Publication date
JP2008195722A (ja) 2008-08-28
ES2328536T3 (es) 2009-11-13
JP2002504810A (ja) 2002-02-12
WO1998050556A2 (en) 1998-11-12
WO1998050556A3 (en) 1999-02-11
AU7471698A (en) 1998-11-27
CA2288374A1 (en) 1998-11-12
US6521423B1 (en) 2003-02-18
JP4458556B2 (ja) 2010-04-28
DE69841015D1 (de) 2009-09-10
JP2009232863A (ja) 2009-10-15
US7429385B2 (en) 2008-09-30
EP0980434A1 (de) 2000-02-23
US20040001854A1 (en) 2004-01-01
HK1023143A1 (zh) 2000-09-01
EP0980434B1 (de) 2009-07-29

Similar Documents

Publication Publication Date Title
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
AR018023A1 (es) Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
DE69733247D1 (de) Humanisiertes grünes-fluoreszenzprotein und methoden
BR0013231A (pt) Complexos citocina-anticorpo múltiplos
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
EP0833912A4 (de) Neues tgf-beta-ahnliches cytokin
DE60144145D1 (de) Subtilisin-variante
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DK0920448T3 (da) Trunkeret gliacellelinie-afledt neurotrof faktor
TR200000175T2 (tr) Endogenik gen aktivasyonu ile eritropoietinin hazırlanması.
ATE212059T1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
DE69702705D1 (de) Kondensierte pyrrolo(2,3-c) carbazole-6-one die die aktivität von gamma interferon potenzieren
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
PT813419E (pt) Moduladores de proteinas reguladoras
PT1200561E (pt) Clone celular recombinante estavel, sua producao e utilizacao
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DK1000154T3 (da) Identificering af humane cellelinjer til produktion af humane proteiner ved endogen genaktivering
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ES2090357T3 (es) Una proteina de union a colageno asi como su preparacion.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties